8-KMaterial AgreementsExhibits & Filings

BIOGEN INC. 8-K Report, Material Agreement (Feb 1, 2017)

Filed February 1, 2017For Securities:BIIB

Summary

Biogen Inc. (BIIB) has reported the execution of a Settlement and License Agreement with Forward Pharma A/S, following shareholder approval from Forward Pharma on February 1, 2017. This agreement, previously outlined in a Letter Agreement on January 17, 2017, signifies a resolution of certain disputes between the two entities. Investors should note that while this license agreement is now effective, it does not settle ongoing patent interference proceedings at the U.S. Patent Trial and Appeal Board (PTAB) or opposition proceedings concerning Forward Pharma's European patent EP 2801355. Biogen and Forward Pharma intend to allow these legal and patent office proceedings to reach their own conclusions. The primary significance for investors lies in the establishment of a licensing framework that could potentially impact Biogen's product portfolio and future revenue streams, depending on the specific terms of the license, which are incorporated by reference from a prior filing. However, the continuation of the patent disputes introduces an element of ongoing risk and uncertainty that investors will need to monitor.

Key Highlights

  • 1Biogen Inc. has finalized a Settlement and License Agreement with Forward Pharma A/S, effective February 1, 2017.
  • 2The agreement was approved by Forward Pharma shareholders at an extraordinary general meeting.
  • 3This marks a significant step in resolving prior disputes between Biogen and Forward Pharma.
  • 4The License Agreement's terms are detailed in a filing incorporated by reference from January 17, 2017.
  • 5Crucially, the agreement does NOT resolve ongoing patent interference proceedings at the PTAB.
  • 6The agreement also does NOT resolve opposition proceedings related to Forward Pharma's European patent EP 2801355.
  • 7Biogen and Forward Pharma will allow patent office and court proceedings to continue to final determination.

Frequently Asked Questions

This 8-K filing announces the official execution and effectiveness of a Settlement and License Agreement between Biogen Inc. and Forward Pharma A/S, following the necessary shareholder approval from Forward Pharma.

No, the agreement explicitly states that it does not resolve the ongoing patent interference proceedings at the U.S. Patent Trial and Appeal Board (PTAB) or the opposition proceedings concerning Forward Pharma's European patent EP 2801355. These proceedings will continue to their final determination.

The implications depend on the specific terms of the license agreement, which are incorporated by reference from a previous filing. It suggests a resolution for certain past disputes, potentially impacting Biogen's access to or use of certain intellectual property. However, the ongoing patent litigation introduces continued uncertainty.

Details of the material terms are incorporated by reference from Biogen's Form 8-K filed on January 17, 2017. The full and complete terms are contained within the License Agreement itself, filed as Exhibit 10.1 with this 8-K report.